Golimumab for the Treatment of Refractory Behcet's Uveitis

NCT04218565 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped only one patient enrolled

Conditions

Behcet Syndrome
Uveitis

Interventions

BIOLOGICAL: Golimumab (GOL)

Sponsor

Wenjie Zheng